Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 110
Filter
1.
Int J Obstet Anesth ; 43: 47-55, 2020 08.
Article in English | MEDLINE | ID: mdl-32044216

ABSTRACT

BACKGROUND: Cesarean delivery is one of the most common surgeries performed worldwide and the adoption of enhanced recovery programs for cesarean delivery is gaining popularity. We tested the hypothesis that implementation of an enhanced recovery program for cesarean delivery would be associated with a decrease in postoperative opioid consumption. METHODS: We compared a retrospective cohort of women delivered by elective cesarean delivery (January 1, 2017 to June 30, 2018) to a prospective cohort exposed to the enhanced recovery protocol (July 1, 2018 to December 31, 2018). The primary outcome was inpatient maternal opioid use, measured as total oral morphine equivalents. Secondary outcomes included postoperative 0-10 pain scores, length of stay, 30-day postoperative complication rates, and hospital re-admissions. RESULTS: Data from 541 patients were analyzed. The enhanced recovery cohort used significantly less oral morphine equivalents compared with the pre-enhanced recovery cohort (60.3 mg vs 104.3 mg, P <0.001). The number of patients who required opioid medication within 24 h of discharge was significantly reduced in the enhanced recovery cohort (41.1% vs 74.6%, P <0.001). There were no significant differences in average pain scores (1.6 vs 1.9, P=0.037). CONCLUSIONS: The implementation of an enhanced recovery program for cesarean delivery was associated with a significant reduction in postoperative opioid consumption throughout hospitalization, with average pain scores remaining <2. Implementation of this program was also associated with an increase in the number of patients who were opioid-free 24 h prior to discharge.


Subject(s)
Analgesics, Opioid/administration & dosage , Cesarean Section , Enhanced Recovery After Surgery , Pain, Postoperative/drug therapy , Adult , Analgesics, Opioid/therapeutic use , Cohort Studies , Female , Humans , Pregnancy , Retrospective Studies
2.
Sci Rep ; 8(1): 7568, 2018 05 15.
Article in English | MEDLINE | ID: mdl-29765102

ABSTRACT

Acute nicotine abstinence in cigarette smokers results in deficits in performance on specific cognitive processes, including working memory and impulsivity which are important in relapse. Cannabidiol (CBD), the non-intoxicating cannabinoid found in cannabis, has shown pro-cognitive effects and preliminary evidence has indicated it can reduce the number of cigarettes smoked in dependent smokers. However, the effects of CBD on cognition have never been tested during acute nicotine withdrawal. The present study therefore aimed to investigate if CBD can improve memory and reduce impulsivity during acute tobacco abstinence. Thirty, non-treatment seeking, dependent, cigarette smokers attended two laboratory-based sessions after overnight abstinence, in which they received either 800 mg oral CBD or placebo (PBO), in a randomised order. Abstinence was biologically verified. Participants were assessed on go/no-go, delay discounting, prose recall and N-back (0-back, 1-back, 2-back) tasks. The effects of CBD on delay discounting, prose recall and the N-back (correct responses, maintenance or manipulation) were null, confirmed by a Bayesian analysis, which found evidence for the null hypothesis. Contrary to our predictions, CBD increased commission errors on the go/no-go task. In conclusion, a single 800 mg dose of CBD does not improve verbal or spatial working memory, or impulsivity during tobacco abstinence.


Subject(s)
Cannabidiol/administration & dosage , Impulsive Behavior/drug effects , Memory/drug effects , Tobacco Use Disorder/psychology , Adult , Bayes Theorem , Cannabidiol/pharmacology , Female , Humans , Male , Memory, Short-Term/drug effects , Random Allocation , Spatial Memory/drug effects , Young Adult
3.
Neuropharmacology ; 142: 72-82, 2018 11.
Article in English | MEDLINE | ID: mdl-29339294

ABSTRACT

Ketamine is a dissociative anaesthetic drug which acts on the central nervous system chiefly through antagonism of the n-methyl-d-aspartate (NMDA) receptor. Recently, ketamine has attracted attention as a rapid-acting anti-depressant but other studies have also reported its efficacy in reducing problematic alcohol and drug use. This review explores the preclinical and clinical research into ketamine's ability to treat addiction. Despite methodological limitations and the relative infancy of the field, results thus far are promising. Ketamine has been shown to effectively prolong abstinence from alcohol and heroin in detoxified alcoholics and heroin dependent individuals, respectively. Moreover, ketamine reduced craving for and self-administration of cocaine in non-treatment seeking cocaine users. However, further randomised controlled trials are urgently needed to confirm ketamine's efficacy. Possible mechanisms by which ketamine may work within addiction include: enhancement of neuroplasticity and neurogenesis, disruption of relevant functional neural networks, treating depressive symptoms, blocking reconsolidation of drug-related memories, provoking mystical experiences and enhancing psychological therapy efficacy. Identifying the mechanisms by which ketamine exerts its therapeutic effects in addiction, from the many possible candidates, is crucial for advancing this treatment and may have broader implications understanding other psychedelic therapies. In conclusion, ketamine shows great promise as a treatment for various addictions, but well-controlled research is urgently needed. This article is part of the Special Issue entitled 'Psychedelics: New Doors, Altered Perceptions'.


Subject(s)
Ketamine/pharmacology , Ketamine/therapeutic use , Psychotropic Drugs/pharmacology , Psychotropic Drugs/therapeutic use , Substance-Related Disorders/drug therapy , Animals , Behavior, Addictive/drug therapy , Humans
4.
Psychol Med ; 46(16): 3383-3395, 2016 12.
Article in English | MEDLINE | ID: mdl-27628967

ABSTRACT

BACKGROUND: Cannabis is a widely used drug associated with increased risk for psychosis. The dopamine hypothesis of psychosis postulates that altered salience processing leads to psychosis. We therefore tested the hypothesis that cannabis users exhibit aberrant salience and explored the relationship between aberrant salience and dopamine synthesis capacity. METHOD: We tested 17 cannabis users and 17 age- and sex-matched non-user controls using the Salience Attribution Test, a probabilistic reward-learning task. Within users, cannabis-induced psychotic symptoms were measured with the Psychotomimetic States Inventory. Dopamine synthesis capacity, indexed as the influx rate constant K i cer , was measured in 10 users and six controls with 3,4-dihydroxy-6-[18F]fluoro-l-phenylalanine positron emission tomography. RESULTS: There was no significant difference in aberrant salience between the groups [F 1,32 = 1.12, p = 0.30 (implicit); F 1,32 = 1.09, p = 0.30 (explicit)]. Within users there was a significant positive relationship between cannabis-induced psychotic symptom severity and explicit aberrant salience scores (r = 0.61, p = 0.04) and there was a significant association between cannabis dependency/abuse status and high implicit aberrant salience scores (F 1,15 = 5.8, p = 0.03). Within controls, implicit aberrant salience was inversely correlated with whole striatal dopamine synthesis capacity (r = -0.91, p = 0.01), whereas this relationship was non-significant within users (difference between correlations: Z = -2.05, p = 0.04). CONCLUSIONS: Aberrant salience is positively associated with cannabis-induced psychotic symptom severity, but is not seen in cannabis users overall. This is consistent with the hypothesis that the link between cannabis use and psychosis involves alterations in salience processing. Longitudinal studies are needed to determine whether these cognitive abnormalities are pre-existing or caused by long-term cannabis use.


Subject(s)
Marijuana Abuse/psychology , Psychoses, Substance-Induced/psychology , Adult , Brain/diagnostic imaging , Brain/metabolism , Cannabis/adverse effects , Case-Control Studies , Dihydroxyphenylalanine/analogs & derivatives , Dopamine/metabolism , Female , Humans , Male , Marijuana Abuse/diagnostic imaging , Marijuana Abuse/metabolism , Neostriatum/diagnostic imaging , Neostriatum/metabolism , Positron-Emission Tomography , Psychoses, Substance-Induced/diagnostic imaging , Psychoses, Substance-Induced/etiology , Psychoses, Substance-Induced/metabolism , Radiopharmaceuticals , Reward , Young Adult
5.
Transl Psychiatry ; 6: e738, 2016 Feb 16.
Article in English | MEDLINE | ID: mdl-26882038

ABSTRACT

Smoking cannabis daily doubles an individual's risk of developing a psychotic disorder, yet indicators of specific vulnerability have proved largely elusive. Genetic variation is one potential risk modifier. Single-nucleotide polymorphisms in the AKT1 and catechol-O-methyltransferase (COMT) genes have been implicated in the interaction between cannabis, psychosis and cognition, but no studies have examined their impact on an individual's acute response to smoked cannabis. A total 442 healthy young cannabis users were tested while intoxicated with their own cannabis-which was analysed for delta-9-tetrahydrocannbinol (THC) and cannabidiol content-and also ± 7 days apart when drug-free. Psychotomimetic symptoms and working memory were assessed on both the sessions. Variation at the rs2494732 locus of the AKT1 gene predicted acute psychotic response to cannabis along with dependence on the drug and baseline schizotypal symptoms. Working memory following cannabis acutely was worse in females, with some suggestion of an impact of COMT polymorphism on working memory when drug-free. These findings are the first to demonstrate that AKT1 mediates the acute response to cannabis in otherwise healthy individuals and implicate the AKT1 pathway as a possible target for prevention and treatment of cannabis psychosis.


Subject(s)
Cannabinoids/genetics , Cannabinoids/pharmacology , Marijuana Smoking/genetics , Mental Disorders/genetics , Mental Disorders/psychology , Proto-Oncogene Proteins c-akt/genetics , Acute Disease , Adolescent , Adult , Female , Genetic Predisposition to Disease/genetics , Genotype , Humans , Male , Polymorphism, Single Nucleotide/genetics , Risk , Sex Factors , Young Adult
6.
Psychopharmacology (Berl) ; 232(14): 2503-17, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25757672

ABSTRACT

RATIONALE: Drug addiction may be characterised by a hypersensitivity to drug rewards and a hyposensitivity to non-drug rewards. This imbalance may become further polarised during acute abstinence. OBJECTIVES: (i) Examine the differences between dependent and occasional smokers in choices for, motivation for and self-reported wanting and liking of cigarette and non-drug rewards. (ii) Examine the effects of 12-h nicotine abstinence on these metrics. METHODS: Dependent (n = 20) and occasional, non-dependent smokers (n = 20) were tested after ad libitum smoking and ≥12-h of nicotine abstinence. A novel task was developed (Drug, Reward and Motivation-Choice (DReaM-Choice)) in which different rewards (cigarettes, music and chocolate) could be won. In each trial, participants chose between two rewards and then could earn the chosen reward via repeated button-pressing. Participants subsequently 'consumed' and rated subjective liking of the rewards they had won. RESULTS: Compared with occasional smokers, dependent smokers made more choices for (p < 0.001), pressed more for (p = 0.046) and reported more wanting (p = 0.007) and liking (p < 0.001) of cigarettes, and also made fewer choices for chocolate (p = 0.005). There were no differences between the groups on button-pressing for chocolate or music. However, the balance between drug and non-drug reward processing was different between the groups across all metrics. Twelve-hour nicotine abstinence led to more cigarette choices (p < 0.001) and fewer music choices (p = 0.042) in both groups. CONCLUSIONS: Nicotine dependence was associated with a hypersensitivity to cigarette rewards, but we found little evidence indicating a hyposensitivity to non-drug rewards. Our findings question the moderating influence of dependence on how acute nicotine abstinence affects reward processing.


Subject(s)
Reward , Substance Withdrawal Syndrome/psychology , Tobacco Use Disorder/psychology , Carbon Monoxide/metabolism , Choice Behavior/drug effects , Craving , Cross-Over Studies , Depression/psychology , Female , Humans , Male , Motivation/drug effects , Nicotine/pharmacology , Pleasure/drug effects , Psychomotor Performance/drug effects , Reading , Young Adult
7.
J Psychopharmacol ; 28(11): 1001-8, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25122044

ABSTRACT

BACKGROUND: Acute recreational use of 3,4-methylenedioxymethamphetamine (MDMA; 'ecstasy') can promote pro-social effects which may alter interpersonal perceptions. AIMS: To explore such effects, this study investigated whether acute recreational use of ecstasy was associated with changes in individual perception of trustworthiness of people's faces and co-operative behaviours. METHOD: An independent group, repeated measures design was used in which 17 ecstasy users were tested on the night of drug use (day 0) and again three days later (day 3); 22 controls were tested on parallel days. On each day, participants rated the trustworthiness of 66 faces, carried out three co-operative behaviour tasks (public good; dictator; ultimatum game) and completed mood self-ratings. RESULTS: Acute ecstasy use was associated with increased face trustworthiness ratings and increased cooperative behaviour on the dictator and ultimatum games; on day 3 there were no group differences on any task. Self-ratings showed the standard acute ecstasy effects (euphoria, energy, jaw clenching) with negative effects (less empathy, compassion, more distrust, hostility) emerging on day 3. CONCLUSIONS: Our findings of increased perceived trustworthiness and co-operative behaviours following use of ecstasy suggest that a single dose of the drug enhances aspects of empathy. This may in turn contribute to its popularity as a recreational drug and potentially to its enhancement of the therapeutic alliance in psychotherapy.


Subject(s)
Cooperative Behavior , N-Methyl-3,4-methylenedioxyamphetamine/pharmacology , Social Perception , Trust/psychology , Affect/drug effects , Case-Control Studies , Facial Expression , Female , Humans , Male , Young Adult
8.
Int J Neuropsychopharmacol ; 17(4): 527-40, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24345398

ABSTRACT

3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine-releaser that is widely used as a recreational drug. Preliminary work has supported the potential of MDMA in psychotherapy for post-traumatic stress disorder (PTSD). The neurobiological mechanisms underlying its putative efficacy are, however, poorly understood. Psychotherapy for PTSD usually requires that patients revisit traumatic memories, and it has been argued that this is easier to do under MDMA. Functional magnetic resonance imaging (fMRI) was used to investigate the effect of MDMA on recollection of favourite and worst autobiographical memories (AMs). Nineteen participants (five females) with previous experience with MDMA performed a blocked AM recollection (AMR) paradigm after ingestion of 100 mg of MDMA-HCl or ascorbic acid (placebo) in a double-blind, repeated-measures design. Memory cues describing participants' AMs were read by them in the scanner. Favourite memories were rated as significantly more vivid, emotionally intense and positive after MDMA than placebo and worst memories were rated as less negative. Functional MRI data from 17 participants showed robust activations to AMs in regions known to be involved in AMR. There was also a significant effect of memory valence: hippocampal regions showed preferential activations to favourite memories and executive regions to worst memories. MDMA augmented activations to favourite memories in the bilateral fusiform gyrus and somatosensory cortex and attenuated activations to worst memories in the left anterior temporal cortex. These findings are consistent with a positive emotional-bias likely mediated by MDMA's pro-monoaminergic pharmacology.


Subject(s)
Cerebral Cortex/drug effects , Functional Neuroimaging/methods , Memory, Episodic , Mental Recall/drug effects , N-Methyl-3,4-methylenedioxyamphetamine/pharmacology , Serotonin Agents/pharmacology , Adult , Double-Blind Method , Emotions/drug effects , Female , Functional Neuroimaging/instrumentation , Humans , Magnetic Resonance Imaging , Male , N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage , Placebos , Serotonin Agents/administration & dosage
9.
Pharmacopsychiatry ; 45(7): 269-74, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22511328

ABSTRACT

BACKGROUND: Ketamine, psychostimulants and cannabis have all been associated with psychotic phenomena but no study has directly compared users of these drugs. AIMS: The aim of this study was to assess schizophrenia proneness and neurocognitive function in individuals dependent upon ketamine, cannabis and cocaine. METHOD: 130 volunteers - 29 'skunk' users, 22 cocaine users, 21 ketamine users, along with 28 'recreational' poly-drug users and 30 drug-naïve controls - were assessed on the Schizophrenia Proneness Instrument, Adult version (SPI-A). They were specifically asked to rate symptoms when not under the acute influence of a psychoactive drug. RESULTS: Ketamine and skunk users manifested the greatest attentional and cognitive disturbances. The symptom profile of the dependent ketamine users was very similar to that of prodromal individuals who transitioned to psychosis. CONCLUSIONS: Given the recent rapid rise in use of high potency cannabis and of ketamine, these findings are important and clinicians should be careful to rule out the effects of persistent drug use, especially in users of ketamine or skunk, when assessing an individual's risk of psychosis. A longitudinal study is needed to differentiate which basic symptoms persist following abstention from ketamine and skunk.


Subject(s)
Cocaine-Related Disorders/psychology , Cognition Disorders/psychology , Ketamine/adverse effects , Marijuana Abuse/psychology , Schizophrenia/chemically induced , Substance-Related Disorders/psychology , Adolescent , Adult , Attention , Case-Control Studies , Cocaine-Related Disorders/complications , Cognition Disorders/complications , Female , Humans , Male , Marijuana Abuse/complications , Middle Aged , Neuropsychological Tests/statistics & numerical data , Psychiatric Status Rating Scales/statistics & numerical data , Risk Factors , Self Report , Substance-Related Disorders/complications
10.
Psychol Med ; 42(1): 161-71, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21733292

ABSTRACT

BACKGROUND: Addicts show both reward processing deficits and increased salience attribution to drug cues. However, no study to date has demonstrated that salience attribution to drug cues can directly modulate inferences of reward value to non-drug cues. Associative learning depends on salience: a more salient predictor of an outcome will 'overshadow' a less salient predictor of the same outcome. Similarly, blocking, a demonstration that learning depends on prediction error, can be influenced by the salience of the cues employed. METHOD: This study investigated whether salient drug cues might interact with neutral cues predicting financial reward in an associative learning task indexing blocking and overshadowing in satiated smokers (n=24), abstaining smokers (n=24) and non-smoking controls (n=24). Attentional bias towards drug cues, craving and expired CO were also indexed. RESULTS: Abstaining smokers showed drug cue induced overshadowing, attributing higher reward value to drug cues than to neutral cues that were equally predictive of reward. Overshadowing was positively correlated with expired CO levels, which, in turn, were correlated with craving in abstainers. An automatic attentional bias towards cigarette cues was found in abstainers only. CONCLUSIONS: These findings provide the first evidence that drug cues interact with reward processing in a drug dependent population.


Subject(s)
Association Learning , Attention , Behavior, Addictive/psychology , Cues , Reward , Tobacco Use Disorder/psychology , Adult , Analysis of Variance , Breath Tests , Carbon Monoxide/analysis , Female , Humans , Male , Motivation , Neuropsychological Tests , Photic Stimulation , Reaction Time , Reinforcement, Psychology , Satiation/physiology , Single-Blind Method , Smoking/psychology , Smoking Cessation/psychology , Tobacco Use Disorder/diagnosis
11.
Psychol Med ; 42(2): 391-400, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21798112

ABSTRACT

BACKGROUND: Cannabis varies considerably in levels of its two major constituent cannabinoids - (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Recently, we found evidence that those who smoked cannabis containing detectable levels of CBD had fewer psychotic-like symptoms than those whose cannabis had no CBD. The present study aimed, first, to replicate those findings and, second, to determine whether protective effects of CBD may extend to other harms of cannabis, such as memory impairment and reduced psychological well-being. METHOD: A total of 120 current cannabis smokers, 66 daily users and 54 recreational users were classified into groups according to whether analysis of their hair revealed the presence or absence of CBD and high versus low levels of THC. All were assessed on measures of psychosis-like symptoms, memory (prose recall; source memory) and depression/anxiety. RESULTS: Lower psychosis-like symptoms were found in those whose hair had CBD compared with those without. However, this was seen only in recreational users, who had higher levels of THC in their hair. Higher THC levels in hair were associated with increased depression and anxiety. Prose recall and source memory were poorer in daily users with high THC levels in hair while recognition memory was better in individuals with CBD present in hair. CONCLUSIONS: CBD attenuates the psychotic-like effects of cannabis over time in recreational users. Higher THC negatively impacts on memory and psychological well-being. These findings raise concerns for the harms stemming from use of varieties such as 'skunk' (sensimillia), which lack any CBD but currently dominate the supply of cannabis in many countries.


Subject(s)
Cannabidiol/pharmacology , Cognition Disorders/prevention & control , Depression/chemically induced , Dronabinol/adverse effects , Illicit Drugs/pharmacology , Marijuana Smoking , Memory/drug effects , Schizotypal Personality Disorder/prevention & control , Adolescent , Adult , Anxiety/chemically induced , Cannabidiol/analysis , Cannabidiol/therapeutic use , Cognition Disorders/chemically induced , Dronabinol/analysis , Dronabinol/pharmacology , Female , Hair/chemistry , Humans , Illicit Drugs/adverse effects , Male , Marijuana Smoking/adverse effects , Psychoses, Substance-Induced/etiology , Psychoses, Substance-Induced/prevention & control , Schizotypal Personality Disorder/chemically induced , Young Adult
12.
Mult Scler ; 16(8): 926-34, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20562161

ABSTRACT

The number of new gadolinium-enhancing lesions discovered via magnetic resonance imaging is a well-established outcome for multiple sclerosis studies, especially Phase II Studies. Due to the high cost of magnetic resonance imaging scans, many investigators select participants for the presence of lesions. While this selection procedure is thought to improve the power of inferences, the effect of screening for baseline activity on parameter estimation and interval coverage has not yet been examined. The objective of this study was to investigate the performance of the negative binomial distribution for modeling lesion count data in multiple sclerosis when patients have been selected for activity on a baseline scan. We performed computer simulations to investigate the influence of the screening process on inferences made using a negative binomial model about treatment effects in two independent samples. We also demonstrate how the statistical properties of screening can be incorporated into trial design. We demonstrate that when the negative binomial distribution is used to model lesion counts, while screening for baseline activity improves point estimation, this practice also has the potential to decrease interval coverage and inflate the Type I error rate. For data that is to be modeled using a negative binomial distribution, screening for baseline activity can create a trade-off between cost effectiveness and a higher than desired false positive rate that must be carefully considered in planning Phase II trials.


Subject(s)
Brain/pathology , Multiple Sclerosis/diagnosis , Multiple Sclerosis/physiopathology , Adult , Binomial Distribution , Clinical Trials, Phase II as Topic , Computer Simulation , Humans , Linear Models , Magnetic Resonance Imaging , Models, Neurological , Poisson Distribution , Research Design
13.
Psychol Med ; 39(6): 951-6, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19017430

ABSTRACT

BACKGROUND: Epidemiological evidence suggests a link between cannabis use and psychosis. A variety of factors have been proposed to mediate an individual's vulnerability to the harmful effects of the drug, one of which is their psychosis proneness. We hypothesized that highly psychosis-prone individuals would report more marked psychotic experiences under the acute influence of cannabis. METHOD: A group of cannabis users (n=140) completed the Psychotomimetic States Inventory (PSI) once while acutely intoxicated and again when free of cannabis. A control group (n=144) completed the PSI on two parallel test days. All participants also completed a drug history and the Schizotypal Personality Questionnaire (SPQ). Highly psychosis-prone individuals from both groups were then compared with individuals scoring low on psychosis proneness by taking those in each group scoring above and below the upper and lower quartiles using norms for the SPQ. RESULTS: Smoking cannabis in a naturalistic setting reliably induced marked increases in psychotomimetic symptoms. Consistent with predictions, highly psychosis-prone individuals experienced enhanced psychotomimetic states following acute cannabis use. CONCLUSIONS: These findings suggest that an individual's response to acute cannabis and their psychosis-proneness scores are related and both may be markers of vulnerability to the harmful effects of this drug.


Subject(s)
Cannabis/adverse effects , Hallucinations/epidemiology , Hallucinations/etiology , Marijuana Abuse/complications , Psychotic Disorders/epidemiology , Psychotic Disorders/etiology , Adolescent , Adult , Analysis of Variance , Case-Control Studies , Female , Hallucinogens , Humans , Male , Middle Aged , Psychiatric Status Rating Scales , United Kingdom/epidemiology , Young Adult
14.
Drug Alcohol Depend ; 95(3): 219-29, 2008 Jun 01.
Article in English | MEDLINE | ID: mdl-18355990

ABSTRACT

Although recreational use of the dissociative anaesthetic drug ketamine is currently increasing, little is known about the phenomenological aspects of its use. We therefore designed a structured interview to examine initiation experiences, positive and negative effects of ketamine use, and concerns about the drug and its long-term effects. Ninety participants (30 frequent users, 30 infrequent 'recreational' users and 30 ex-users who had abstained from use for at least 3 months) were interviewed and reported drug use was verified by hair sample analysis. The most appealing aspects of ketamine for two-thirds of users were "melting into the surrounding", "visual hallucinations", "out-of-body experiences" and "giggliness". Unappealing effects for half of users were "memory loss" and "decreased sociability". Frequent ketamine users expressed more concerns than other groups about long-term effects on physical health problems, especially K-cramps and cystitis, whereas ex-users were more concerned about mental health problems. Addictive/dependent patterns of behaviour were also a concern: the majority of frequent users reported using the drug without stopping until supplies ran out and the mean increase in dosage in this group was six-fold from initiation to current use. We have identified specific health issues which seem uniquely related to ketamine use. Additionally, the dependence on ketamine frequently reported by users may be a cause for concern as its popularity grows and substance misuse services should be made aware of this when clients present in the future.


Subject(s)
Illicit Drugs , Ketamine , Substance-Related Disorders/epidemiology , Adult , Attitude , Female , Health Status , Humans , Male , Mental Disorders/epidemiology , Substance-Related Disorders/urine , Surveys and Questionnaires
15.
Psychol Med ; 38(9): 1331-40, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18177527

ABSTRACT

BACKGROUND: The attention-grabbing properties of drugs to drug-using individuals have been well documented and recent research has begun to suggest that such attentional bias may be related to the severity of drug dependency. Dependence on ketamine has been reported anecdotally but no systematic study has investigated this phenomenon. We aimed to explore attentional biases to incentive stimuli in different populations of ketamine users. METHOD: Using a dot-probe paradigm, attentional bias to both drug-related and money-related stimuli was investigated in 150 participants: 30 frequent ketamine users, 30 infrequent ketamine users, 30 ex-ketamine users, 30 poly-drug users and 30 non-drug-using controls. Two stimulus presentation times were used (200 and 2000 ms) to investigate whether attentional bias was as a result of an automatic or a more conscious attentional shift. Participants also rated the degree to which stimuli used in the dot-probe paradigm were pleasurable. RESULTS: Frequent ketamine users demonstrated an attentional bias to both types of incentive stimuli only at the short stimulus presentation interval and this was significantly correlated with degree of ketamine use. No attentional biases were observed in any of the other groups. All groups rated money stimuli as more pleasurable than neutral stimuli. CONCLUSIONS: These data support incentive models of drug use and demonstrate the ability of the attentional bias paradigm to discriminate recreational drug users from those with more dependent patterns of use. Ketamine is a potentially dependence-forming drug.


Subject(s)
Attention/drug effects , Ketamine/administration & dosage , Motivation , Substance-Related Disorders/psychology , Visual Perception/drug effects , Adult , Alcohol Drinking/psychology , Amphetamine/administration & dosage , Cocaine/administration & dosage , Educational Status , Female , Humans , Male , Photic Stimulation/methods , Reaction Time/drug effects , Severity of Illness Index , Task Performance and Analysis
16.
Amino Acids ; 34(4): 587-96, 2008 May.
Article in English | MEDLINE | ID: mdl-18071842

ABSTRACT

The Phenomenex EZ:faast amino acid analysis kit is available for gas (GC) or liquid (LC) chromatographic analysis of amino acids (AA) using mass spectrometry (MS) and other GC detectors. We used it for rapid GC determination of plasma tryptophan, its brain uptake competitors (Val, Leu, Ile, Phe and Tyr) and many other amino acids. Based on solid-phase extraction, this fast method enables one person to process two plasma samples in 8-10 min and six samples in approximately 15 min up to GC injection and a 7-min GC run per plasma sample. Using a Perkin-Elmer Clarus 500 GC, a Total Chrome software, a flame-ionisation detector (FID) and norvaline as internal standard, we used this method to analyse approximately 1,000 plasma samples from normal subjects undergoing acute tryptophan depletion and loading tests. The limit of detection for most amino acids is 1 nmol/ml (1 microM) and in many cases less. With manual injection, coefficients of variation for the above six amino acids were 1.5-6.2% (intra-assay) and 3.8-9.7% (inter-assay). This simple, rapid and elegant method will be valuable to the amino acid analyst and researcher, as it can save much manpower time and meet urgent emergency requests and the demands of a high-throughput laboratory.


Subject(s)
Amino Acids/blood , Brain/metabolism , Reagent Kits, Diagnostic , Tryptophan/blood , Amino Acids/pharmacokinetics , Binding, Competitive/drug effects , Chromatography, Gas/methods , Chromatography, Gas/standards , Female , Fluorometry/methods , Humans , Indicators and Reagents , Linear Models , Male , Reference Values , Reproducibility of Results , Sensitivity and Specificity , Solid Phase Extraction , Time Factors , Tryptophan/pharmacokinetics
17.
Clin Exp Dermatol ; 31(3): 368-71, 2006 May.
Article in English | MEDLINE | ID: mdl-16681578

ABSTRACT

Spitz naevi are usually solitary lesions. Multiple Spitz naevi are extremely rare and reported as widespread (disseminated) or grouped (agminated). We report two cases of multiple Spitz naevi and review their aetiology and treatment.


Subject(s)
Neoplasms, Multiple Primary/pathology , Nevus, Epithelioid and Spindle Cell/pathology , Skin Neoplasms/pathology , Abdomen , Adult , Back , Biomarkers, Tumor/analysis , Biopsy, Needle , Child , Humans , Ki-67 Antigen/analysis , Male , Neoplasms, Multiple Primary/chemistry , Nevus, Epithelioid and Spindle Cell/chemistry , S100 Proteins/analysis , Skin Neoplasms/chemistry
19.
Br J Anaesth ; 94(3): 390-2, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15579486

ABSTRACT

A case is described of extensive subcutaneous emphysema with rapid and life-threatening airway obstruction. The incident followed inadvertent removal of a chest drain in a patient with a persistent air leak from an iatrogenic pneumothorax. The pneumothorax had developed during pacemaker insertion.


Subject(s)
Airway Obstruction/etiology , Chest Tubes , Medical Errors/adverse effects , Pneumothorax/therapy , Subcutaneous Emphysema/etiology , Aged , Female , Humans , Intraoperative Complications/therapy , Pacemaker, Artificial , Pneumothorax/diagnostic imaging , Pneumothorax/etiology , Subcutaneous Emphysema/diagnostic imaging , Tomography, X-Ray Computed
20.
Br J Dermatol ; 148(3): 434-43, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12653734

ABSTRACT

BACKGROUND: Hydrophilic drugs are poorly absorbed when applied topically, due to low partitioning through the lipid matrix of the stratum corneum. Cutaneous blood flow rapidly clears the absorbed drug, which may result in low tissue levels. This is of importance for topically applied drugs whose site of action is within the epidermis or dermis. Dermal drug levels can be measured using cutaneous microdialysis, which is a means of continuously sampling substances from the dermal extracellular fluid. OBJECTIVES: To measure the contribution of stratum corneum barrier and microvascular perfusion in determining dermal tissue levels of hydrophilic drugs (aciclovir and penciclovir) in vivo. METHODS: Studies were performed using microdialysis of the volar surface of the forearm of healthy volunteers (n = 55) over a 5-h collection period. Stratum corneum was removed by tape stripping, and barrier disruption quantified by measurement of transepidermal water loss (TEWL); dermal microvascular perfusion was modulated by inclusion of noradrenaline in the microdialysis perfusate. RESULTS: With intact skin and normal cutaneous blood flow the concentration of penciclovir recovered was below assay threshold (0.05 ng x mL(-1). With noradrenaline-induced local vasoconstriction, the area under the curve of drug absorbed through normal skin (+/- SEM) was 13.3 +/- 2.9 ng mL(-1) h(0-5) for penciclovir and 27.6 +/- 10.6 ng mL(-1) h(0-5) for aciclovir. Removal of the stratum corneum (to glistening) by tape stripping increased penciclovir absorption by 1300-fold and aciclovir absorption by 440-fold, confirming the stratum corneum as the major barrier to hydrophilic drug absorption. Sequential barrier disruption by tape stripping gave a close correlation between penciclovir concentration absorbed per hour and barrier disruption measured by TEWL (r2 = 0.9283). There was a 15.6-fold difference in the recovery of penciclovir through barrier-deficient skin with and without cutaneous blood flow. There was no relationship between fibre depth and amount of drug dialysed, which suggests free movement of antiviral drug on reaching the aqueous environment of the dermis. CONCLUSIONS: This study defines for the first time the relationship between the degree of mechanical barrier impairment and drug absorption at the same anatomical site in humans, and the role of blood flow in drug clearance in vivo.


Subject(s)
Acyclovir/analogs & derivatives , Acyclovir/pharmacokinetics , Antiviral Agents/pharmacokinetics , Skin/metabolism , Acyclovir/administration & dosage , Administration, Topical , Adult , Aged , Antiviral Agents/administration & dosage , Dermis/blood supply , Epidermis/physiology , Female , Guanine , Humans , Male , Microdialysis/methods , Middle Aged , Skin/blood supply , Skin Absorption/drug effects , Solubility , Water Loss, Insensible
SELECTION OF CITATIONS
SEARCH DETAIL
...